<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Pediatr</journal-id>
      <journal-title>European Journal of Pediatrics</journal-title>
      <issn pub-type="ppub">0340-6199</issn>
      <issn pub-type="epub">1432-1076</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17588171</article-id>
      <article-id pub-id-type="pmc">2292480</article-id>
      <article-id pub-id-type="publisher-id">547</article-id>
      <article-id pub-id-type="doi">10.1007/s00431-007-0547-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Calligaris</surname>
            <given-names>Lorenzo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Marchetti</surname>
            <given-names>Federico</given-names>
          </name>
          <address>
            <phone>+39-040-3785454</phone>
            <fax>+39-040-3785362</fax>
            <email>marchetti@burlo.trieste.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tommasini</surname>
            <given-names>Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ventura</surname>
            <given-names>Alessandro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Pediatrics, Institute of Child Health, Children&#x2019;s Hospital IRCCS Burlo Garofolo, Via dell&#x2019;Istria 65/1, 34137 Trieste, Italy </aff>
        <aff id="Aff2"><label>2</label>Department of Reproductive and Developmental Sciences, University of Trieste, Trieste, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>23</day>
        <month>6</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2008</year>
      </pub-date>
      <volume>167</volume>
      <issue>6</issue>
      <fpage>695</fpage>
      <lpage>696</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>3</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>7</day>
          <month>6</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5&#x2013;10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin&#x2014;the protein involved in FMF&#x2014;has a role in activating the proinflammatory cytokine interleukin (IL)-1&#x3B2;. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Familial Mediterranean fever</kwd>
        <kwd>Colchicine resistance</kwd>
        <kwd>Anakinra</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2008</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Case report</title>
      <p>A 15-year-old girl with familial Mediterranean fever (FMF) was admitted to our hospital because of the persistence of recurrent fever attacks (twice a month), accompanied by chest and abdominal pain with headache, despite taking colchicine at a high dose (2&#xA0;mg/kg per day). She suffered severe discomfort and complained of several school absences.</p>
      <p>Acute phase reactants [erythrocyte sedimentation rate (ESR) 110, C-reactive protein (CRP) 43&#xA0;mg%] and serum interferon-&#x3B3; (125.4&#xA0;pg/ml) were high during the crises. There was no proteinuria, but given the severity of the clinical picture, we performed a rectal biopsy to definitely exclude the presence of amyloidosis and it was negative.</p>
      <p>Anakinra was started at 50&#xA0;mg/day (1&#xA0;mg/kg per day) subcutaneously, without stopping colchicine. Approval was obtained from an Ethics Committee (Burlo Garofolo Health Authority).</p>
      <p>In the following 3&#xA0;months the patient developed only three mild episodes of abdominal pain without fever, which resolved in a few hours. During these episodes acute phase reactants were negative. Moreover, serum interferon-&#x3B3; was low (23&#xA0;pg/ml).</p>
      <p>After 3&#xA0;months, anakinra was discontinued to confirm its real efficacy, without stopping colchicine. Following this interruption, the girl complained of eight fever attacks in 3&#xA0;months accompanied by abdominal pain, vomiting, chest pain, and headache. Anakinra was reintroduced. Since then (15&#xA0;months of follow-up), the patient has been in good health, without any fever attacks or abdominal or chest pain.</p>
      <p>There have been no adverse effects due to anakinra, apart from minor local stinging and erythema at the injection sites, which gradually diminished.</p>
    </sec>
    <sec id="Sec2" sec-type="discussion">
      <title>Discussion</title>
      <p>Colchicine is the recommended treatment of FMF since it can prevent the febrile attacks and the development of amyloidosis, even though a few patients develop amyloidosis also when on colchicine treatment [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. However, approximately one third of the patients have a partial remission and about 5&#x2013;10% are nonresponders [<xref ref-type="bibr" rid="CR3">3</xref>]; another 2&#x2013;5% do not tolerate the drug well [<xref ref-type="bibr" rid="CR3">3</xref>]. In single case reports several drugs (interferon-&#x3B1;, infliximab, thalidomide, etanercept) have been suggested as a possible alternative treatment for these cases [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p>Anakinra is a recombinant form of the human interleukin (IL)-1-receptor antagonist that targets type I IL-1-receptor which is expressed in many tissues. There are some studies and case reports that show a good efficacy of anakinra in a severe autoinflammatory syndrome (CINCA, chronic infantile neurological cutaneous and articular syndrome) [<xref ref-type="bibr" rid="CR2">2</xref>] and other recurrent hereditary periodic fevers [<xref ref-type="bibr" rid="CR4">4</xref>]. Despite the elevated costs (approximately 50 &#x20AC; per 100&#xA0;mg) its use appears justified in some inflammatory diseases that lack alternative treatments.</p>
      <p>Since pyrin&#x2014;the protein involved in FMF&#x2014;activates the precursor form of IL-1&#x3B2; into its biologically active fragments there is a rationale for testing anakinra in FMF [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Moreover, anakinra did appear to be effective in suppressing acute phase reactants in a patient with FMF (a nonresponder to the treatment with colchicine) and amyloidosis [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
      <p>In our case, the addition of anakinra to colchicine had a dramatic therapeutic benefit without relevant side effects. As the febrile attacks recurred after discontinuing anakinra and disappeared again after reintroduction, we believe in the real therapeutic efficacy of this drug. In light of the present evidence [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>], colchicine should be continued in order to prevent further developments of amyloidosis.</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chae</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Masters</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Kastner</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1&#x3B2; production</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>9982</fpage>
          <lpage>9987</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0602081103</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith JB, Kastner DL (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1&#x3B2; production. Proc Natl Acad Sci USA 103:9982&#x2013;9987 <pub-id pub-id-type="pmid">16785446</pub-id></citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldbach-Mansky</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dailey</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Canna</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Gelabert</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rubin</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Brewer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zalewski</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wiggs</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Karp</surname>
              <given-names>BI</given-names>
            </name>
            <name>
              <surname>Aksentijevich</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pucino</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Penzak</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Haverkamp</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Fuhlbrigge</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Shaharm</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jarvis</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>O&#x2019;Neil</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vehe</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Beitz</surname>
              <given-names>LO</given-names>
            </name>
            <name>
              <surname>Gardner</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hannan</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Warren</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Horn</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Cole</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Paul</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Pham</surname>
              <given-names>TH</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wesley</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hoffmann</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Butman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kastner</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
          <article-title>Neonatal-onset multisystem inflammatory disease responsive to interleukin-1&#x3B2; inhibition</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>355</volume>
          <fpage>581</fpage>
          <lpage>592</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa055137</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaharm B, Jarvis JN, O&#x2019;Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman J, Kastner DL (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1&#x3B2; inhibition. N Engl J Med 355:581&#x2013;592 <pub-id pub-id-type="pmid">16899778</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kallinich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Haffner</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Niehues</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huss</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lainka</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Neudorf</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Schafer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stojanov</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Timmann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Keitzer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ozdogan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ozen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement</article-title>
          <source>Pediatrics</source>
          <year>2007</year>
          <volume>119</volume>
          <fpage>e474</fpage>
          <lpage>e483</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.2006-1434</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, Schafer C, Stojanov C, Timmann C, Keitzer R, Ozdogan H, Ozen S (2007) Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 119:e474&#x2013;e483 <pub-id pub-id-type="pmid">17242135</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nevyjel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pontillo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Calligaris</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tommasini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>D&#x2019;Osualdo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Watheram</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Granzotto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crovella</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barbi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ventura</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic and therapeutic insights in a severe case of mevalonate kinase deficiency</article-title>
          <source>Pediatrics</source>
          <year>2007</year>
          <volume>119</volume>
          <fpage>e523</fpage>
          <lpage>e527</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.2006-2015</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nevyjel M, Pontillo A, Calligaris L, Tommasini A, D&#x2019;Osualdo A, Watheram HR, Granzotto M, Crovella S, Barbi E, Ventura A (2007) Diagnostic and therapeutic insights in a severe case of mevalonate kinase deficiency. Pediatrics 119:e523&#x2013;e527 <pub-id pub-id-type="pmid">17261617</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Familial mediterranean fever: revisiting an ancient disease</article-title>
          <source>Eur J Pediatr</source>
          <year>2003</year>
          <volume>162</volume>
          <issue>7&#x2013;8</issue>
          <fpage>449</fpage>
          <lpage>454</lpage>
          <pub-id pub-id-type="doi">10.1007/s00431-003-1223-x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ozen S (2003) Familial mediterranean fever: revisiting an ancient disease. Eur J Pediatr 162(7&#x2013;8):449&#x2013;454 <pub-id pub-id-type="pmid">12751000</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seyahi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ozdogan</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Celik</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ugurlu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yazici</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2006</year>
          <volume>24</volume>
          <issue>5 Suppl 42</issue>
          <fpage>S099</fpage>
          <lpage>S103</lpage>
        </citation>
        <citation citation-type="display-unstructured">Seyahi E, Ozdogan H, Celik S, Ugurlu S, Yazici H (2006) Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 24(5 Suppl 42):S099&#x2013;S103 </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
